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Multiple myelomaThe deregulation of B cell differentiation has been shown to contribute to autoimmune disorders, hematological
cancers, and aging. We provide evidence that the retinoic acid-producing enzyme aldehyde dehydrogenase 1a1
(Aldh1a1) is an oncogene suppressor in speciﬁc splenic IgG1+/CD19− and IgG1+/CD19+ B cell populations.
Aldh1a1 regulated transcription factors during B cell differentiation in a sequential manner: 1) retinoic acid
receptor alpha (Rara) in IgG1+/CD19− and 2) zinc ﬁnger protein Zfp423 and peroxisome proliferator-activated
receptor gamma (Pparg) in IgG1+/CD19+ splenocytes. In Aldh1a1−/− mice, splenic IgG1+/CD19− and IgG1+/
CD19+ B cells acquired expression of proto-oncogenic genes c-Fos, c-Jun, andHoxa10 that resulted in splenomeg-
aly. HumanmultiplemyelomaB cell lines also lack Aldh1a1 expression; however, ectopicAldh1a1 expression res-
cued Rara and Znf423 expressions in these cells. Our data highlight amechanismbywhich an enzyme involved in
vitamin A metabolism can improve B cell resistance to oncogenesis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The deregulation of B cell differentiation has been shown to play a
causal role in autoimmune disorders, carcinogenesis, and aging [1]. B
cells differentiate from B-lymphoid progenitors in the bone marrow
and progress through many stages during differentiation to ultimately
express B cell receptor (BCR). Lymphocytes expressing surface IgM
migrate to the spleen [2], where self-reactive splenic B cells undergo
apoptosis; others become responsive to T-cell-dependent and T-cell-
independent antigens. The various B-cell populations are compartmen-
talized in different splenic zones, including red pulp,marginal zone, and
white pulp. After pathogen exposure, they complete differentiation in
germinal centers [2]. Speciﬁc populations of B cells can undergo alterna-
tive differentiation. For instance, puriﬁed mouse splenic B cells responda1; AP1, activator protein 1 a
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ights reserved.to stimulationwith cytokines, anti-CD38, anti-CD40, anti-μ, and retinoic
acid (RA) by enriching IgG1+ and CD138+ B cell populations and genes
involved in the regulation of Ig somatic hypermutation and class
switching [3]. In these B cells, RA contributed to the suppression of
activation-induced deaminase (Aid), transcriptional regulators of differ-
entiation (Pax5), and neoplastic transformation t(9;14) [3,4]. Oncogenic
processes further diversify in B lymphoma cells [5]. The physiological
mechanisms responsible for the formation of speciﬁc B cell subsets
have remained unexplored.
The studies with dietary vitamin A (retinol or retinyl esters)
highlighted a possible role for this pathway in speciﬁc B cell responses.
Dietary vitamin A content inﬂuenced IgA production against T-cell de-
pendent and T-cell independent type 2 antigens at mucosal locations
[6]. Vitamin A deﬁciency in the diet diminishes immune responses
and increases mortality [7–10]. These responses may be partially im-
proved by supplementation with either vitamin A or its metabolite RA,
arguing for RA as a mediator of these responses. The function of RA in
B cell studies in vitro revealed that multiple aspects of B cell biology
are RA-sensitive [10,11]. RA accelerated differentiation of a subset of
proliferating lymphoid progenitor cells into B cells by targeting the on-
cogenes c-myc and cyclin D3, cytokines, and NFκB, as well as kinase
p38/CDK2 [12,13]. RA treatment also promoted differentiation ofmalig-
nant B cells, alone or in combination with rosiglitazone, an agonist for
3219R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227the nuclear receptor PPARγ [14]. The understanding of RA in immune
function is incomplete. For example, a recent trial in Guinea–Bissau
revealed a paradoxically higher mortality in girls supplemented with
vitamin A than in placebo group [15]. In this study we dissected the
role of endogenous vitamin A metabolism on gene regulation in B cells.
An increase in the intracellular RA concentrations is generated in re-
sponse to various hormonal, dietary, and inﬂammatory stimuli andmay
be considered as a factor in endogenous differentiation of B cell subsets
[11,16]. RA is produced sequentially. Alcohol dehydrogenases (ADH and
SDR/RDH) oxidize retinol to retinaldehyde, which is dehydrogenated
into RA by the members of aldehyde dehydrogenase-1 family of en-
zymes: ALDH1a1, ALDH1a2, and ALDH1a3 [17]. The principal mecha-
nism of RA action is through the activation of RA receptors (RAR). RA
binding to RAR induces its heterodimerization with retinoid X receptor,
and binding to cognate response element (RARE) sequences in the pro-
moters of target genes [18]. In addition, RA regulates a plethora of signal-
ing and transcriptional pathways [19], including a Zfp423-dependent
induction of Pparg expression [20]. Paracrine RA production by ALDH1
enzymes in dendritic cells plays an important role in B cell homing to
the mucosa, and promotes IgA isotype class switching [21,22]. The role
of RA-generating enzymes in B cells has remained unexplored. Here,
we investigated the transcriptional function of ALDH1a1 in murine B
cell subsets and in human multiple myeloma B cell lines.2. Materials and methods
2.1. Reagents
We purchased reagents from Sigma-Aldrich (St. Louis, MO) and cell
culturemedia from Invitrogen (Carlsbad, CA) unless otherwise indicated.
Anti-mouse antibodies were: CD19 from BD Biosciences (San Jose, CA)
and β-galactosidase from Abcam (Cambridge, MA).2.2. Animal studies
All experimental protocols were approved by the Institutional
Animal Care and User Committee. Water and regular chow (Harlan
Laboratories, Indianapolis, IL) were available ad libitum in all mouse
studies.
Study 1 employed Tg RARE-Hspa1b/lacZ (denoted as RARE-lacZ) re-
porter mice developed by Dr. J. Rossant using a transgenic construct
containing 3 copies of the 32 bp RARE placed upstream of the mouse
heat shock protein 1B promoter and β-galactosidase gene (lacZ) [23].
Female mice were purchased from the Jackson Laboratory (Bar Harbor,
ME). Three RARE-lacZ and three wild-type C57BL/6J (WT) female mice
(12–15 weeks old) were fed regular chow throughout this study.
Study 2: Aldh1a1−/−mice were previously generated in the labora-
tory of G. Duester [24] and characterized for their metabolic responses
[20,25,26]. Aldh1a1−/− (n = 10) and WT (n = 9) 13–14 month old
male and female mice were used for these studies. Mice were fed regu-
lar chow diet. Blood was collected by cardiac puncture in EDTA-
containing tubes. The spleens isolated from 3 randomly-selected fe-
males were used for IgG1+/CD19− and IgG1+/CD19+ B-cell separation.
The remaining spleens and other organs were used for other analyses.2.3. Human cells
Leukopacks (American Red Cross, Columbus, OH) were obtained
from healthy donors under an Institutional Review Board-approved
procurement protocol. Peripheral blood mononuclear cells (PBMC)
were cultured in RPMI 1640 media (Invitrogen) supplemented with
10% fetal bovine serum (ICN Biomedicals, Irvine, CA) and kept at 37 °C
in a 5% CO2/air incubator.2.4. Flow cytometry analysis (FACS)
Splenocyte suspension was obtained from whole spleens dissected
from 4 WT and 4 Aldh1a1−/− mice (2 males and 2 females in each
group). Brieﬂy, spleens were collected and mononuclear cell suspen-
sions were prepared by mechanical disruption with the aid of a cell
strainer (BD Biosciences, San Jose, CA) followed by brief incubation in
NH4Cl (0.08%) to remove red blood cells. Splenocyteswere resuspended
in ﬂuorescence-activated cell sorting buffer (FACS; PBS containing 0.1%
BSA and 0.1% sodium azide) at 5 × 105/100 μL. Cells were stained with
a panel of antibodies from AbD Serotec (Bio-Rad Laboratories, Inc.,
Hercules, CA) and available isotype controls. All antibodies were
primary, non-conjugated with the exception of MHC class II which
were directly conjugated to ﬂuorescein isothiocyanate (FITC) and
Alexa Fluor 647 (BD Biosciences), respectively. Secondary antibodies
of either phycoerythrin (PE; 5 μL) or ﬂuorescein isothiocyanate (FITC;
1 μL) were purchased from AbD Serotec and were used at various dilu-
tions (1:10, 1:50, and 1:100) [27]. Samples were analyzed using BD
Accuri ﬂow cytometer and analyzed with BD Accuri Flow analysis soft-
ware (BD Biosciences).
2.5. Puriﬁcation of IgG1/CD19− and IgG1/CD19+ B cells
Splenic B cell subsets were obtained from four WT and Aldh1a1−/−
female and one male mice. They were puriﬁed by automated magnetic
cell separation (autoMACS, Miltenyi Biotec). The cell suspensions were
incubated with microbeads conjugated with anti-mouse CD19. The
CD19− and CD19+ populations were separated by autoMACS. The
CD19− and CD19+ fraction was further incubated with a biotinylated
rat anti-mouse γ1 (clone G1-7.3, BD Biosciences) and streptavidin-
conjugated microbeads. Populations of IgG1+/CD19− and IgG1+/
CD19+ were separated by autoMACS. Throughout, we denoted these
populations as CD19− and CD19+. The purity (N98%) of the cell popula-
tion was conﬁrmed by FACS.
2.6. RNA isolation and quantitative real time PCR (qRT-PCR)
Total RNAwas prepared using the RNeasy kit (Qiagen, Valencia, CA).
qRT-PCR was performed with predesigned assays (Applied Biosystems,
Foster City, CA) using a 7900HT Fast Real-Time PCR System, TaqMan de-
tection system, and validated primers (Applied Biosystems, Foster City,
CA) in triplicate as described [16]. ThemRNA expression was calculated
based on Tata-box binding protein (TBP) expression for normalization
using the comparative Ct method.
2.7. NanoString gene expression proﬁling
The digital multiplexed NanoString nCounter mouse inﬂammation
expression assay (NanoString Technologies) was performed with
100 ng of total RNA according to the manufacturer's instructions. RNA
was isolated from CD19− and CD19+ fraction isolated from 3 female
WT and Aldh1a1−/− mice. NanoString's nCounter technology is based
on direct detection of target molecules using color-coded molecular
barcodes, providing a digital quantiﬁcation of the number of target mol-
ecules [28]. Total mRNA (5 μL) was hybridized overnight with nCounter
Reporter (20 μL) probes in hybridization buffer and nCounter Capture
probes (5 μL). The hybridizations were incubated at 65 °C for 16–20 h
in excess of probes to ensure that each target ﬁnds a probe pair. Excess
probes were removed using two-step magnetic bead based puriﬁcation
on the nCounter Prep Station. The hybridizationmixture containing tar-
get/probe complexes was allowed to bind to magnetic beads containing
complementary sequences on the Capture Probe and washed followed
by a sequential binding to sequences on the Reporter Probe. Biotinylated
capture probe-bound samples were immobilized and recovered on a
streptavidin-coated cartridge. The abundance of speciﬁc target mole-
cules was then quantiﬁed using the nCounter Digital Analyzer to count
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in each sample with a CCD camera. For each assay, a high-density scan
(600 ﬁelds of view) was performed at the highest standard data resolu-
tion, 600 ﬁelds of view (FOV) that is the dynamic range and level of sen-
sitivity in the system. Images were processed internally into a digital
format and were normalized using the NanoString nSolver software
analysis tool. Counts were normalized for all target RNAs in all samples
based on the positive control RNA to account for differences in hybridi-
zation efﬁciency and post-hybridization processing, including puriﬁca-
tion and immobilization of complexes. Subsequently, a normalization
of mRNA content was performed using six internal reference house-
keeping genes that were included within the mouse inﬂammatory
panel: Cltc, Gapdh, Gusb, Hprt1, Pgk1, and Tubb. The average wasFig. 1. Activation of retinoic acid receptor response element (RARE) accompanies splenic red p
RARE-LacZmice (n = 3 from each group)whichwere injected every 48 h, up to a total of 3 inje
500 μM RA stock solution in ethanol immediately before injection. Vehicle PBS solution contain
sphere. Total injected RA amount was 1.5 nmol per mouse (0.15 μg/dose). Immediately after
Immunohistochemistry was performed with anti-β-galactosidase antibody. Heterogeneous b
zone (F) (10× magniﬁcation). The RARE responses in adipose and hepatic tissues were desc
(n = 9)). Inset shows the representative whole spleen images of WT and Aldh1a1−/− mice
from WT and Aldh1a1−/− (KO) mice from the same study (n = 3 per group). (D) FACS analy
(n = 4) mice. P, signiﬁcance levels, Mann–Whitney U test. (E) Expression of germinal center
bars) mice was analyzed by TaqMan assays (WT: n = 3; Aldh1a1−/− n = 5). Data were normnormalized by background counts for each sample obtained from the
average of the eight negative control counts. Counts were corrected by
subtracting the mean and 2 times standard deviation value of the nega-
tive control from the counts obtained for each target RNA.2.8. Immunohistochemistry
Spleens and kidney were embedded in parafﬁn. Immunohistochem-
ical analysis of spleens from WT and RARE-lacZ mice was performed
with rabbit polyclonal β-galactosidase antibody (1:1000 dilution). Im-
ages were obtained using Olympus M081 IX50 and Pixera Viewﬁnder
3.0 software.ulp development, which depends on Aldh1a1. (A) RARE activation was studied inWT and
ctionswith 1 mL PBS (vehicle) without or with RA (500 nM). RAwas added into PBS from
ed 1 μL ethanol. All RA solutions were protected from light and stored under argon atmo-
the third injection, mice were harvested and their spleens were embedded in parafﬁn.
rown β-galactosidase-positive areas were found in red pulp (RP) compared to follicular
ribed in [25]. (B) Weight of spleens (left panel, Study 2. Aldh1a1−/− (n = 10) and WT
. (C) Representative hematoxylin & eosin staining of parafﬁn embedded spleen section
sis of splenocyte suspension isolated from whole spleens of Aldh1a1−/− (n = 4) and WT
markers in the total spleen lysates isolated from WT (white bars) and Aldh1a1−/− (black
alized by TBP. Signiﬁcant difference was determined using Mann–Whitney U test.
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U266B1 (U266) andRPMI8226were purchased fromAmerican Type
Culture Collection (Manassas, VA), other B cell lines were provided byFig. 2. Increased proportion of CD19+B cells contributes to splenomegaly inAldh1a1−/−mice. (A
using automated magnetic cell separation and double selection with IgG1 and CD19 antibodie
plasma markers (CD138) (C) as well as differentiation (CD79a, D) and naive (B220, E) B cell
(n = 3 from each group). Data were normalized by TBP. Asterisk, signiﬁcant difference in expre
U test. (F–I) Representative immunostaining characteristics (from n = 5 per group) of tota
splenocytes and isolated CD19− and CD19+ B cells were simultaneously analyzed with CD19,
bodies. For all gates, the percent and total count of all cells staining positive for both antibodieDr. D.M. Benson, Jr. All human B cells were maintained in 15% fetal
bovine serum/RPMI 1640 medium as previously described [29].
Human full length Aldh1a1 cDNA expression vector was purchased
from OriGene (Rockville, MD). U266 cells (6 × 106 per tube) were) CD19− and CD19+ B cells were isolated fromwhole spleens ofWT and Aldh1a1−/−mice
s (n = 5 per group). Cell populations were quantiﬁed. (B–E) Expression of CD19 (B) and
markers were quantiﬁed in the isolated CD19− and CD19+ B cells using TaqMan assays
ssion between CD19− and CD19+ B cells of the same genetic background.Mann–Whitney
l splenocytes (F) and isolated CD19− and CD19+ B cells (G) using FACS analysis. Total
CD138 (H), and B220 (I) antibodies conjugated with different secondary ﬂuorescent anti-
s were determined.
3222 R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227transfected with human full length Aldh1a1 (PCMV6-XL5, OriGene) or
empty vector, using the Amaxa Cell Line Nucleofector Kit C (Lonza,
NJ). Transient transfectionswere performed inNIH-3T3ﬁbroblasts lack-
ing Pparg expression using Fugene (Roche, South San Francisco, CA) and
the following vectors: HoxA10 luciferase reporter vector (Switchgear
Genomics, Menlo Park, CA), control Renilla reporter vector, and murine
full length Rara, Pparg, and Rxra constructs according to a previous pro-
tocol [16,20].2.10. Statistical analysis
Oncomine cancer transcriptome database (https://www.oncomine.
org) was used as a publicly available platform for data-mining in
mRNA-expression studies [30]. The search terms ‘Aldh1a1 and multiple
myeloma’ were used to identify relevant studies with sufﬁcient sample
numbers to compare expression of Aldh1a1 in multiple myeloma and
plasma cells in the same dataset. One such dataset was identiﬁed [31].
All other data group comparisonswere performed usingMannWhitney
U-test unless otherwise indicated, and correlations were examined by
Pearson's test.Fig. 3. Diminished expression of RA-generating Aldh1 enzymes and Rara in B cells from
Aldh1a1−/− vs. WT mice. (A–C) CD19− and CD19+ B cells (same as in Fig. 2A, n = 5 per
group) isolated fromWT (left panels) and Aldh1a1−/− (right panels) mice were examined
for the expression of (A)major retinaldehyde (Rald)-generating enzymesRdh10 andAdh4,
(B) RA-generating enzymes Aldh1a1, Aldh1a2, and Aldh1a3, and (C) Rara. Gene expression
was analyzed by TaqMan assays and normalized with TBP. P, signiﬁcant difference in ex-
pression between CD19− and CD19+ B cells. Mann–Whitney U test (throughout this
ﬁgure).3. Results
3.1. Vitamin A metabolism regulates immature B cell populations in
the spleen
The topography of RAR activation in mouse spleen was assessed in
RARE-lacZ mice treated with and without RA (Fig. 1A). RARE activation
in the spleen was heterogeneous and was predominant in the red pulp
compared to lymphoid follicles in both non-treated and RA-treated
samples.
RA is produced by an ALDH1 family of enzymes ALDH1a1, ALDH1a2,
andALDH1a3. InAldh1a1−/−mice, the spleen is enlarged (256%, Fig. 1B)
compared to spleens in WT mice. Spleen architecture is altered in
Aldh1a1−/− vs. WT mice (Fig. 1C) due to the increased proportion of
CD19+ and B220+B cell populations (Fig. 1D). Germinal centermarkers
MTA3 and BCL6 [32] were expressed at similar levels in Aldh1a1−/− and
WT spleens, indicating that theywere not impaired by Aldh1a1deﬁcien-
cy (Fig. 1E). The expression of Cd1d1was 61% lower in Aldh1a1−/− than
inWT splenocytes. The association of splenomegalywith the increase in
CD19+ and B220+ B cell populations suggests that differentiation could
be impaired in Aldh1a1−/−mice.
Differentiated CD19+ B cells are one of the major leukocyte popula-
tions in red pulp. Among them, the IgG1+B cell populationwas sensitive
to RA in pharmacological studies [3,4]. Therefore, we used magnetic cell
separation technology to separate IgG1+/CD19− and IgG1+/CD19+
splenic B cell populations (Fig. 2) to test for effects of Aldh1a1 deﬁciency
on transcriptional regulation of critical immune pathways in B cells. We
termed IgG1+/CD19− as CD19− and IgG1+/CD19+ as CD19+ B cells
throughout the publication. The splenomegaly seen in Aldh1a1−/−
mice (Fig. 1B) was associated with an increased number of CD19+ B
cells (171%) compared to WT (Fig. 2A). The purity and characteristics
of CD19+ B cell population were examined using CD19 expression
(Fig. 2B) and FACS analysis (Fig. 2F–G). Although both cell populations
expressed similar low levels of plasma cell marker CD138 (Fig. 2C),
both CD19+ and CD19− B cell populations were CD138-positive in
FACS analysis (Fig. 2H). CD19+ B cells also expressed a mature B cell
marker CD79a (Fig. 2D). In contrast, an expression of pro-, mature and
activated B cell marker B220 was lower in CD19+ than in CD19− B
cells (Fig. 2E). Both groups were B220 positive in FACS analysis
(Fig. 2I). Notably, the expression of all major studied B cell markers
was similar in WT and Aldh1a1−/− mice. However, Aldh1a1 deﬁciency
was associated with an increase in the CD19+ B cell population and
splenomegaly.3.2. Dissimilar expression of Aldh1 in CD19− and CD19+ B cell populations
To investigatewhether CD19− andCD19+B cellsmetabolize vitamin
A, we examined the expression of enzymes involved in synthesis of Rald
(Fig. 3A) and RA (Fig. 3B). The expression of major Rald-generating en-
zymes (Rdh10, Adh4) was similar between CD19− and CD19+ B cells
(Fig. 3A, left panel). Aldh1a1 deﬁciency moderately decreased Rdh10
levels (−24%, Fig. 3A, right panel). In contrast, expression of the RA-
generating Aldh1a1 and Aldh1a2 enzymes was markedly reduced to
6.4% and 18%, respectively, in CD19+ compared to CD19− B cells
(Fig. 3B left panel). Aldh1a1 was the predominantly expressed member
of ALDH1 family of enzymes in both CD19− and CD19+ B cells
(Fig. 3B, left panel). Aldh1a1 deﬁciency suppressed the expression of
Aldh1a2 in CD19− and CD19+ B cells (Fig. 3B, right panel). Thus,
CD19+ B cells in Aldh1a1−/− mice had reduced levels of all RA-
producing enzymes. The change in Aldh1a1 expression also inﬂuenced
expression of Rara, the primary transcription factor regulated by RA
[18]. Rara was reduced to 44% in CD19+ vs. CD19− B cells in WT mice
(Fig. 3C, left panel). In Aldh1a1−/− CD19− B cells, Rara expression was
decreased to 60% compared to WT CD19− B cells and became similar
to that seen in CD19+ B cells (Fig. 3C, right panel).
3.3. Aldh1a1 deﬁciency results in oncogene expression in CD19+ B cells
To identify the mechanisms altering the number and properties of
CD19+ B cells in Aldh1a1−/− mice, we analyzed the classic markers of
3223R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227B cell apoptosis (caspase 3), proliferation (Mki67) (Fig. 4A), and differ-
entiation (Ebf1 and Pax 5) in all groups (Fig. 4B). The expression of
these genes was not altered between Aldh1a1−/− vs. WT genotype in
the isolated CD19− and CD19+ B cells. Ebf1 and Pax5 expressions were
higher in differentiated CD19+ than in CD19− splenocytes; however,
these levels were not inﬂuenced by WT and Aldh1a1−/− genotypes.
To identify genes increasing CD19+ B cell population in Aldh1a1−/−
mice, we quantiﬁed the expression of 250 inﬂammatory genes using
NanoString Technologies' nCounter System. Gene expression was nor-
malized using six housekeeping genes. The gene cluster analysis re-
vealed that Aldh1a1 inﬂuenced expression of proto-oncogenes (c-Fos,
c-Jun, and Mafk kinase) and an opsonin (C1qb) (Fig. 4C). Aldh1a1−/−
CD19− B cells expressed 267% higher levels of c-Fos than WT cells
(Fig. 3D). These changes were in agreement with decreased expression
of Rara, a known suppressor of c-Fos, in CD19− B cells (Fig. 3C) [33].
Aldh1a1 deﬁciency affected CD19+ B cells more than CD19− B cells.
Speciﬁcally c-Fos and c-Jun expression levels were 711% and 294%Fig. 4. Increased expression of proto-oncogenic genes in isolated splenic CD19− and CD19+Aldh
(white bars) and Aldh1a1−/− (black bars) group of mice (Fig. 2, n = 5 per group). (A & B) Expr
ferentiation markers (Ebf1 and Pax5) were semi-quantiﬁed using TaqMan assays. Data (n = 3
CD19− and CD19+ B cells of the same genetic background. Mann–Whitney U test. (C) Selected
spectively) obtained using NanoString Technologies' nCounter mouse inﬂammation panel.
inﬂammation-related genes and six internal reference genes (www.nanostring.com). Red boxes
of genes. (D) Expression levels of c-Fos and c-Jun, using NanoString Technologies' nCountermou
P, signiﬁcant difference between WT and Aldh1a1−/− B cells, Mann–Whitney U test (n = 3 pehigher than those inWT cells (Fig. 4D). This ﬁndingwas paradoxical be-
cause CD19− B cells expressed 15.5-times higher Aldh1a1 and 5.5-times
higher Aldh1a2 levels than those seen in CD19+ B cells from WT mice
(Fig. 3B). We hypothesized that another Aldh1a1-sensitive suppressor
of c-Fos/c-Jun is active in CD19+ B cells.
3.4. Aldh1a1 limits oncogene expression CD19+ B cells by a sequential
induction of Zfp423 and Pparg
ALDH1 enzymes can induce the transcription factor Zfp423 which,
in turn, controls the expression of the anti-proliferative and anti-
inﬂammatory transcription factor Pparg in adipocytes [20]. In splenic B
cells, expression of Aldh1a1 positively correlated with Zfp423, speciﬁ-
cally in CD19+ B cells (P b 0.001) (Fig. 5A). Zfp423 was markedly up-
regulated in CD19+ (625%) vs. CD19− WT B cells. However, this in-
crease was abolished in Aldh1a1−/− CD19+ B cells (Fig. 5B), suggesting
a regulatory role of Aldh1a1. The Zfp423 expression levels were also1a1−/− vs.WTB cells. CD19− andCD19+B cellswere isolated from spleens of the sameWT
ession of apoptosis (caspase3) and proliferation markers (Mki67) (A) as well as B cell dif-
per group) were normalized by TBP. Asterisk, signiﬁcant difference in expression between
expression heat maps (red and green colors represent high and low expression levels, re-
The nCounter GX Mouse Inﬂammation Kit (NanoString Technologies) consists of 184
showed statistically signiﬁcant (n = 3per group,P b 0.05,Mann–WhitneyU test) clusters
se inﬂammation panel insets show the extracted expression heatmaps for c-Fos and c-Jun.
r group).
3224 R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227correlated with Pparg levels in CD19+ B cells (Fig. 5C). In agreement
with Zfp423's role in the induction of Pparg [20], only CD19+ B cells
expressed less Pparg (−75%) in Aldh1a1−/− than WT splenocytes
(Fig. 5D). PPAR response element (PPRE) has been identiﬁed in the pro-
moter of transcription factor Hoxa10 [34], a key inducer of human
lymphomyelopoiesis [35]. To examine a possible role for Pparg in the
regulation of the Hoxa10 promoter, we performed transfection studies
in NIH 3T3 ﬁbroblasts, a cell line lacking endogenous Pparg expression.
Forced expression of Pparg inhibited activation of Hoxa10 promoter in a
gene dose-dependentmanner (Fig. 5E). Pparg expression alsomarkedly
suppressed Hoxa10 promoter activation in a ligand (rosiglitazone)-de-
pendent manner (Fig. 5F). In contrast, both Rxra and Rara only moder-
ately activated Hoxa10 promoter reporter in the presence or absence
of RA ligand (Fig. 5G). Consistent with a regulatory role of Pparg,
CD19+ B cells expressed 400% higher levels of Hoxa10 in Aldh1a1−/−
than in WT mice (Fig. 5H). Thus, elevated Hoxa10 expression in
Aldh1a1−/− CD19+ B cells could be a direct effect of deﬁcient Pparg ex-
pression. Other transcriptional mechanisms may also regulate Hoxa10in CD19− B cells. Since elevated expression of proto-oncogenes AP1
(c-fos/c-jun) andHoxa10 is involved in the development ofmultiplemy-
eloma (MM), we examined the Aldh1a1 expression in B-cell related
cancers.
3.5. RA and/or Aldh1a1 rescues Rara and Zfp423 expressions in myeloma
B cell lines
A search of publicly-available cancer gene expression data using
Oncomine analysis revealed that B-cell-related cancer cell lines express
low levels of Aldh1a1 compared to other cancer cell lines (Fig. 6A). In
our studies in peripheral bloodmononuclear cells isolated from healthy
donors (Fig. 6B),Aldh1a1was a predominantly expressed gene from the
ALDH1 family. This pattern of expressionwasmarkedly changed inMM
cell lines U266B1, RPMI8266, OPM2, L363, and MM1s (Fig. 6B). L363
MM cells expressed no Aldh1 genes. Aldh1a1 expression was lower
compared to the expression of Aldh1a2 and Aldh1a3 in these MM cells.
In agreement, the Oncomine analysis ﬁndings [31] showed reduced
Aldh1a1 expression in 74 human MM patients, compared to healthy
plasma cell controls (Fig. 6C). The RA stimulation of L363 MM cells in-
creased expression of Znf423, a human analog of murine Zfp423 in
MM cells (Fig. 6D). Aldh1a1 overexpression was even more effective
in up-regulating suppressors of proto-oncogenes. The expression of a
full-length human Aldh1a1 construct increased Aldh1a1 expression in
U266 MM cells without altering expression of Aldh1a2 and Aldh1a3
(Fig. 6E). This overexpression of Aldh1a1 resulted in an increased ex-
pression of both Rara (30%) and Znf423 (500%) in U266 MM cells
(Fig. 6F).
4. Discussion
Humoral immune responses are mediated by mature follicular B
cells with the help of T cells in splenic germinal centers and, to a
minor extent (~10%), by marginal-zone B cells [2]. Cytokines/cytokine
receptors, Ig recognition, and antigen presented by APCs, dendritic
cells, and/or macrophages can initiate differentiation of B cells and for-
mation of germinal centers to achieve Ig production [11]. In these pro-
cesses, dietary vitamin A or RA can facilitate differentiation by classic
Pax5-dependent pathways in some splenic B cell population [11,12].
Our study revealed a key role for RA-generating ALDH1 enzymes in B
cell biology. Aldh1a1 expression in immature CD19+ B cells and MM B
cells is critical for the establishment of a transcriptional proﬁle (Fig.7)
that prevents oncogene expression.Fig. 5. Aldh1a1 inﬂuences expression of Zfp423 and Pparg genes inCD19+B cells, suppress-
ing promoter activity of Hoxa10. (A & B) Correlation (A) between Aldh1a1 expression
(Aldh1a1 expression was shown in Fig. 3B) and expression levels of Zfp423 (B) in CD19
− (white bars or circles) and CD19+ (black bars or circles) B cells. Gene expressionwas an-
alyzed in triplicate by TaqMan assays (n = 3 per group). (C & D) Correlation (C) between
Zfp423 expression (B) and expression levels of Pparg (D) in CD19− (white bars or circles)
and CD19+ (black bars or circles) B cells (n = 6 in each correlation group). Gene expres-
sionwas analyzed by TaqMan assays in triplicate. Asterisk, signiﬁcant difference in expres-
sion between CD19− and CD19+ B cells of the same genetic background; P, signiﬁcant
difference between WT and Aldh1a1−/− B cells, Mann–Whitney U test. (E–G) Promoter
analysis of Hoxa10 in NIH3-3T3 ﬁbroblasts lacking Pparg (n = 12). (E) NIH3-3T3 ﬁbro-
blasts were transiently transfected with full-length Pparg overexpression or empty
(mock) vector (0). 48 h after transfection the expression of Hoxa10 was measured by
TaqMan assay. P, Pearson correlation. (F) Promoter analysis of Hoxa10 in NIH3-3T3 ﬁbro-
blasts transiently transfected with mock or full-length Pparg overexpression vectors. 24 h
after transfection, cells were stimulated with different rosiglitazone concentrations for
15 h (n = 3 in each stimulated group). #, signiﬁcantly different between cells expressing
mock and Pparg vector; asterisk, signiﬁcant difference between Pparg expressing cells
stimulated with vehicle and rosiglitazone. (G) Cell was transiently transfected with
empty vector (Mock) or Rara and Rxra overexpression vectors (n = 9). 24 h after trans-
fection, cells were stimulated with different retinoic acid (RA, n = 3) concentrations for
27 h. #, signiﬁcantly different between cells expressing empty vector and Rara and/or
Rxra; asterisk, signiﬁcantdifference betweenRara/Rxra expressing cell stimulatedwith ve-
hicle (ethanol/DMSO, 50/50%) and RA, Mann–Whitney U test. (H) Expression levels of
Hoxa10 in CD19− (white bars or circles) and CD19+ (black bars or circles) B cells mea-
sured by TaqMan assay (n = 3 for each group). Signiﬁcance was determined as in (D).
Fig. 6. Impaired Aldh1a1 expression in humanmultiplemyeloma B cell lines could be rescued by RA or Aldh1a1 overexpression that increased Rara and Znf423 levels. (A) Relative expres-
sion of Aldh1a1 in hematological (n = 3) and other cancer cell lines (n = 28). Data were obtained from data mining in Oncomine database and based on the publication by Rhodes et al.
[30]. (B) Expression levels of Aldh1 genes were measured in human PBMC cells (n = 7 donors) and in myeloma cell lines (n = 5): RPMI, U266B1, OPM2, L363, and MM1s (n = 3 per
measurement). P, signiﬁcant difference in expression between Aldh1a1, Aldh1a2, and Aldh1a3 enzymes within the same cell population. (C) Analysis of Aldh1a1 gene expression in
human multiple myeloma (n = 74), plasma cells (n = 37) andmonoclonal gammopathy of undetermined signiﬁcance (MGUS) (n = 5). Gene expression database analysis (see Mate-
rials andmethods) identiﬁed by Zhan et al. (2002) [31] data shown here (adapted fromOncomine; Rhodes et al. (2007) [30]). The plot boxes are lined at lower,median and upper quartile
score values; whiskers extend to 10th and 90th percentiles; dots mark minimum and maximum values. (D) RA treatment of L363 myeloma cell lines increases Znf423 expression. L363
cells weremaintained in RPMImedium containing 1% of UV treated FBS,which is depleted of retinoids. L363 cells weremaintained in thismedium24 h prior to RA stimulation and during
treatment with RA. Znf243 expression was measured 48 h after RA treatment (n = 3). P, signiﬁcant difference, Mann–Whitney U test. (E) Expression levels of Aldh1a1 (left panel) and
Aldh1a2 and Aldh1a3 (black and white bars in the right panel) in U266B1 cells transiently transfected with empty (−) or human full length Aldh1a1 overexpression plasmid (+)
(n = 3 independent experiments). Expression levels weremeasured in triplicate using TaqMan assays 24 h after transfection. P, signiﬁcant difference, Mann–Whitney U test. (F) Expres-
sion of Rara (left panel) and Znf423 (human analog of mouseZfp423, right panel) in U266B1 (black bar) transfected with empty (−) and Aldh1a1 overexpression vector (+) (n = 3 in-
dependent experiments). P, signiﬁcant difference, Mann–Whitney U test.
3225R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227Aldh1a1 expression was consistently predominant over other RA-
generating enzymes from the ALDH1 family in healthy B cells in mice
and humans (Figs. 3B and 6B). Aldh1a1-dependent pathways in isolated
B cell populations were different from those altered by administration of
RA or manipulation of dietary vitamin A content. RA administration has
two major sites of action related to B cell functions. It improves antigen
presentation and IgA production atmucosal sites [15] and induces prolif-
eration and differentiation of IgG1+ splenocytes in germinal centers
[3,4,11]. In these scenarios, endogenous RA was produced by APCs and
stimulated ﬁnal B cell differentiation in germinal centers [36]. Weshowed that under physiological conditions, intense endogenous RAR
activity was associated with red pulp (Fig. 1A). In agreement, we found
the highest Aldh1a1 and Rara expression levels in IgG1+CD19− (CD19
−) B cell populations (Figs. 2, 3). CD19− is a potentially heterogeneous
population comprised of naive and mature B220+ B cell populations.
Both Rara and Aldh1 expressions were decreased in the IgG1+CD19+
(CD19+) population. This loss of endogenous RA production in CD19+
B cells could later allow them to receive a paracrine signaling of RA-
producing APCs after they enter germinal centers. The physiological ex-
pression of Aldh1 genes in CD19+ vs. CD19− B cells in WT mice
Fig. 7. Schematic diagram of the Aldh1a1 dependent pathways in CD19− and CD19+
IgG1+ B cell populations in the spleen. Aldh1a1 is expressed at higher levels in CD19−
vs. CD19+ B cells. Aldh1a1 also shapes the expression of transcription factors in CD19+
population, where it is responsible for the induction of Zfp423 and Pparg. Expression of
Pparg suppressed proto-oncogenes c-Fos, c-Jun, and Hoxa10.
3226 R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227prevented increase in expression of oncogenes c-Fos/c-Jun and Hoxa10
(Figs. 4D, 5H), due to the Aldh1a1-dependent induction of oncogene
suppressors (Zfp423 and Pparg) in these cells (Fig. 5B, D). The disruption
of Aldh1a1 regulation in Aldh1a1−/−micemarkedly compromised B cell
oncogene proﬁles during differentiation (Figs. 4, 5), increased red pulp
proportions, and reduced expression of Cd1d1 that is involved in inter-
actions between T and B cells (Fig. 1D, right panel).
Classic CD19− and CD19+B cell differentiation via Ebf1 and Pax5 [37]
appear to be not impaired in the absence of Aldh1a1 (Fig. 4B). The break-
through in the understanding of themechanism increasing CD19+ pop-
ulation came from the NanoString analysis (Fig. 4C). Aldh1a1 deﬁcient
CD19+ B cells expressed proto-oncogenes c-Fos/c-Jun forming the tran-
scription factor AP1. Elevated c-Fos/c-Jun and also Hoxa10 expressions
are distinct features of B cell-dependent hematological neoplasms, in-
cluding lymphomas and multiple myeloma [38–40]. Hoxa10 overex-
pression in hematopoietic cells is sufﬁcient to impair murine and
human lymphomyelopoiesis and leads to acute myeloid leukemia
[35,41]. Notably, all ﬁve human multiple myeloma (MM) cell lines
expressed 100-times less Aldh1a1 than normal PBMC cells (Fig. 6B).
Similar ﬁndings in B cell cancers and in plasma cells from MM patients
were available from other studies [31] that we identiﬁed through data-
base analysis (Fig. 6A, C). Themajor RA-generating enzyme in these can-
cer cells was Aldh1a2 suggesting that the loss of Aldh1a1 contributed to
B cell neoplastic pathology. Previous studies showed that only combined
treatment of RA and rosiglitazone can induce U266 differentiation [14].
Our data provide a mechanism and rationale for the treatment of MM B
cells lacking Aldh1a1with RAR and PPARγ agonists.
Increased c-Fos expression in Aldh1a1−/− CD19− B cells appears
to be consistent with the known competitive relation between AP1
and RARα activated by RA [33]. Indeed, Aldh1a1−/− CD19− B cells
had reduced expression of both Aldh1a1 and Rara (Fig. 3). Forced ex-
pression of Aldh1a1 in U266 cells can readily increase Rara expres-
sion (Fig. 6). An unexpected result of our study was the ﬁnding of
more profound transcriptional changes in CD19+ compared to
CD19− B cells expressing markedly less Aldh1a1 in WT mice
(Fig. 3B). WTCD19+ cells expressed higher levels of proto-
oncogenes c-Fos, c-Jun, and Hoxa10 than Aldh1a1−/− CD19+ B
cells. Increased number of CD19+ cells contributed partially to the
splenomegaly in Aldh1a1−/− mice. This phenomenon could be
based on Aldh1a1-mediated changes on the transcriptome. During
adipogenesis, Aldh1a1 induces expression of the transcription factor
Zfp423, which in turn induces Pparg [20,42]. Previous investigations
highlighted competition between Pparg and c-Fos/c-Junwithout en-
gaging PPRE [43,44]. PPRE response element was found in the
Hoxa10 promoter [34]. Our studies connected Aldh1a1 to the regula-
tion of all these transcription factors in B cells (Fig.7). Aldh1a1 didnot support Zfp423 expression in CD19− B cells probably due to
the speciﬁc transcriptional environment. It is possible that high
Aldh1a1 levels in CD19− B cells produced RA for paracrine signaling
that induced Zfp423 in CD19+ B cells. These regulatory mechanisms
remain to be investigated in the future. We found that Aldh1a1 is re-
quired for the Zfp423 induction in differentiating CD19+ population
(Fig. 5B). Zfp423 and Pparg levels were higher in CD19+ B cells inWT
compared to Aldh1a1−/− mice. This link was suggested by a signiﬁ-
cant correlation in CD19+ B cells (Fig. 5C). The causative link be-
tween Aldh1a1 and Zfp423 expressions was demonstrated in
human U266 MM cells. Aldh1a1 expression rescued Znf423 (human
analog of mouse Zfp423) in U266 MM cells (Fig. 6F). RA treatment
of MM cells can also rescue Znf423 expression (Fig. 6D), suggesting
that ALDH1a1 acts in part via autocrine RA generation. Since Pparg
is induced by Znf423, the short (24 h) transfection period was not
sufﬁcient to also observe signiﬁcant increase in Pparg expression.
However, the relationship between Zfp423 and Pparg has been wide-
ly documented [20,42]. Pparg induction by Aldh1a1 appears to be a
critical event, because Pparg was an effective suppressor of
Hoxa10, a key transcription factor perturbing myeloid and lymphoid
differentiation in mice and humans [34,35,41]. Pparg inhibited the
promoter of Hoxa10, while Rara and Rxra only modestly regulated
this transcription factor (Fig. 5F, G). Consequently, Hoxa10 was up-
regulated in Aldh1a1−/− CD19+ B cells expressing less Pparg. Stud-
ies investigating the effects of vitamin A-deﬁcient diets reported
splenomegaly and an increase in plasma IgG1 levels in mouse
models of autoimmune disorders [45], whereas the production of
speciﬁc IgG1 antibodies in the immunized mice was impaired [46].
Multiple mechanisms have been proposed to explain these phenom-
ena, including RA-dependent production of IFNγ from T cells [47]
and dendritic CD103+ cell subsets [48], but the role of B cells was
unclear. Our data highlight an autocrine and/or paracrine ALDH1
function in differentiating B cells that regulates two key transcrip-
tional oncogene suppressors Rara and Pparg. This suggests a gene–
environment paradigm for early-stage deregulation of oncogene
proﬁles in IgG1+ B cell subsets through compromised vitamin A
metabolism.
5. Conclusion
Our ﬁndings showed the critical role of the retinoic acid-generating
ALDH1a1 enzyme in the sequential induction of oncogene suppressors
Rara in IgG1+/CD19− B cells and Zfp423/Pparg in IgG1+/CD19+ B cells
during B cell differentiation. In the absence of these suppressors, B
cells acquire oncogene Ap1 and Hoxa10 expressions that lead to
IgG1+/CD19+ B cell expansion and splenomegaly. Reduced expression
of Aldh1a1 and oncogene suppressors Rara, Zfp423, and Pparg is a char-
acteristic property of malignant human multiple myeloma B cells. Im-
portantly, ectopic expression of Aldh1a1 or RA effectively rescues Rara
and/or Zfp423 expression. The understanding of the role of ALDH1a1
in B cell differentiation can shed light on the early stages in the develop-
ment of malignant hematological disorders and may lead to the devel-
opment of novel therapeutics.
Funding
This research was supported by Food Innovation Center, Ofﬁce for
International Affairs and Center for Advanced Functional Foods Re-
search and Entrepreneurship at OSU, Daskal Foundation (O.Z., R.Y.)
and Multiple Myeloma Opportunities for Research and Education
(MMORE, D.M.B.Jr). The project described was supported by award
number grant UL1TR000090 from the National Center For Advancing
Translational Sciences and the Cancer Center Support Grant
(CA016058) (O.Z). This study was also supported in part by a research
grant (CA100865) from the Department of Defense Congressionally
Directed Medical Research Programs (C.E.A.). The content is solely the
3227R. Yasmeen et al. / Biochimica et Biophysica Acta 1833 (2013) 3218–3227responsibility of the authors and does not necessarily represent the
ofﬁcial views of the National Center for Research Resources or the
National Institutes of Health.
Acknowledgements
We thank Dr. C. Ross (Pennsylvania State University) for the helpful
discussion. We express our gratitude to Kirsteen Maclean (NanoString
Technologies) and the Nucleic Acid Shared Resource at The Ohio State
University (OSU) for excellent technical and intellectual support.
References
[1] D.K. Dunn-Walters, A.A. Ademokun, B cell repertoire and ageing, Curr. Opin.
Immunol. 22 (2010) 514–520.
[2] P. Matthias, A.G. Rolink, Transcriptional networks in developing and mature B cells,
Nat. Rev. Immunol. 5 (2005) 497–508.
[3] Q. Chen, A.C. Ross, Inaugural article: vitamin A and immune function: retinoic acid
modulates population dynamics in antigen receptor and CD38-stimulated splenic
B cells, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14142–14149.
[4] Q. Chen, A.C. Ross, Retinoic acid promotes mouse splenic B cell surface IgG expres-
sion andmaturation stimulated by CD40 and IL-4, Cell. Immunol. 249 (2007) 37–45.
[5] J.M. Phillips-Quagliata, A.M. Faria, J. Han, D.H. Spencer, G. Haughton, P. Casali, IgG2a
and IgA co-expression by the natural autoantibody-producing murine B lymphoma
T560, Autoimmunity 33 (2001) 181–197.
[6] C.H. Kim, Roles of retinoic acid in induction of immunity and immune tolerance,
Endocr. Metab. Immune Disord. Drug Targets 8 (2008) 289–294.
[7] A. Amouzou, O. Habi, K. Bensaid, Reduction in child mortality in Niger: a countdown
to 2015 country case study, Lancet 380 (2012) 1169–1178.
[8] MMWR Morb. Mortal. Wkly. Rep. 56 (2007) 1237–1241.
[9] G.D. Hussey, M. Klein, A randomized, controlled trial of vitamin A in children with
severe measles, N. Engl. J. Med. 323 (1990) 160–164.
[10] A. Ertesvag, S. Naderi, H.K. Blomhoff, Regulation of B cell proliferation and differen-
tiation by retinoic acid, Semin. Immunol. 21 (2009) 36–41.
[11] A.C. Ross, Q. Chen, Y. Ma, Vitamin A and retinoic acid in the regulation of B-cell de-
velopment and antibody production, Vitam. Horm. 86 (2011) 103–126.
[12] X. Chen, B.L. Esplin, K.P. Garrett, R.S. Welner, C.F. Webb, P.W. Kincade, Retinoids
accelerate B lineage lymphoid differentiation, J. Immunol. 180 (2008) 138–145.
[13] D. Donjerkovic, C.M. Mueller, D.W. Scott, Steroid- and retinoid-mediated growth
arrest and apoptosis in WEHI-231 cells: role of NF-kappaB, c-Myc and CKI
p27(Kip1), Eur. J. Immunol. 30 (2000) 1154–1161.
[14] H. Huang, D. Wu, J. Fu, G. Chen, W. Chang, H.C. Chow, A.Y. Leung, R. Liang, All-trans
retinoic acid can intensify the growth inhibition and differentiation induction effect
of rosiglitazone on multiple myeloma cells, Eur. J. Haematol. 83 (2009) 191–202.
[15] M.J. Jorgensen, A.B. Fisker, E. Sartono, A. Andersen, C. Erikstrup, I.M. Lisse, M.
Yazdanbakhsh, P. Aaby, C.S. Benn, The effect of at-birth vitamin A supplementation
on differential leucocyte counts and in vitro cytokine production: an immunological
study nested within a randomised trial in Guinea–Bissau, Br. J. Nutr. (2012) 1–11.
[16] R. Yasmeen, S.M. Jeyakumar, B. Reichert, F. Yang, O. Ziouzenkova, The contribution of
vitamin A to autocrine regulation of fat depots, Biochim. Biophys. Acta 1821 (2012)
190–197.
[17] G. Duester, Retinoic acid synthesis and signaling during early organogenesis, Cell
134 (2008) 921–931.
[18] P. Germain, P. Chambon, G. Eichele, R.M. Evans, M.A. Lazar, M. Leid, A.R. De Lera, R.
Lotan, D.J. Mangelsdorf, H. Gronemeyer, International Union of Pharmacology. LX.
Retinoic acid receptors, Pharmacol. Rev. 58 (2006) 712–725.
[19] O. Ziouzenkova, Vitamin A metabolism: challenges and perspectives, Vitam. Miner.
Elem. 1 (2012) E106.
[20] B. Reichert, R. Yasmeen, S.M. Jeyakumar, F. Yang, T. Thomou, et al., Concerted action
of aldehyde dehydrogenases inﬂuences depot-speciﬁc fat formation, Mol.
Endocrinol. 25 (2011) 799–809.
[21] D.M. Duriancik, K.A. Hoag, Vitamin A deﬁciency alters splenic dendritic cell subsets
and increases CD8(+)Gr-1(+) memory T lymphocytes in C57BL/6J mice, Cell.
Immunol. 265 (2010) 156–163.
[22] J.R. Mora, M. Iwata, B. Eksteen, S.Y. Song, T. Junt, et al., Generation of gut-homing
IgA-secreting B cells by intestinal dendritic cells, Science 314 (2006) 1157–1160.
[23] J. Rossant, R. Zirngibl, D. Cado, M. Shago, V. Giguere, Expression of a retinoic acid re-
sponse element-hsplacZ transgene deﬁnes speciﬁc domains of transcriptional activ-
ity during mouse embryogenesis, Genes Dev. 5 (1991) 1333–1344.
[24] X. Fan, A. Molotkov, S. Manabe, C.M. Donmoyer, L. Deltour, M.H. Foglio, A.E. Cuenca,
W.S. Blaner, S.A. Lipton, G. Duester, Targeted disruption of Aldh1a1 (Raldh1) pro-
vides evidence for a complexmechanism of retinoic acid synthesis in the developing
retina, Mol. Cell. Biol. 23 (2003) 4637–4648.[25] R. Yasmeen, B. Reichert, J. Deiuliis, F. Yang, A. Lynch, et al., Autocrine function of al-
dehyde dehydrogenase 1 as a determinant of diet- and sex-speciﬁc differences in
visceral adiposity, Diabetes 62 (2013) 124–136.
[26] O. Ziouzenkova, G. Orasanu, M. Sharlach, T.E. Akiyama, J.P. Berger, et al.,
Retinaldehyde represses adipogenesis and diet-induced obesity, Nat. Med. 13
(2007) 695–702.
[27] M. Sherger, W. Kisseberth, C. London, S. Olivo-Marston, T.L. Papenfuss, Identiﬁcation
of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs,
BMC Vet. Res. 8 (2012) 209.
[28] G.K. Geiss, R.E. Bumgarner, B. Birditt, T. Dahl, N. Dowidar, et al., Direct multiplexed
measurement of gene expression with color-coded probe pairs, Nat. Biotechnol.
26 (2008) 317–325.
[29] Y. Dai, T.H. Landowski, S.T. Rosen, P. Dent, S. Grant, Combined treatment with the
checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis
in drug-sensitive and -resistant myeloma cells through an IL-6-independent mech-
anism, Blood 100 (2002) 3333–3343.
[30] D.R. Rhodes, S. Kalyana-Sundaram, S.A. Tomlins, V. Mahavisno, N. Kasper, R.
Varambally, T.R. Barrette, D. Ghosh, S. Varambally, A.M. Chinnaiyan, Molecular con-
cepts analysis links tumors, pathways, mechanisms, and drugs, Neoplasia 9 (2007)
443–454.
[31] F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, et al., Global gene expression
proﬁling of multiple myeloma, monoclonal gammopathy of undetermined signiﬁ-
cance, and normal bone marrow plasma cells, Blood 99 (2002) 1745–1757.
[32] T. Okada, S. Moriyama, M. Kitano, Differentiation of germinal center B cells and fol-
licular helper T cells as viewed by tracking Bcl6 expression dynamics, Immunol. Rev.
247 (2012) 120–132.
[33] X.F. Zhou, X.Q. Shen, L. Shemshedini, Ligand-activated retinoic acid receptor inhibits
AP-1 transactivation by disrupting c-Jun/c-Fos dimerization, Mol. Endocrinol. 13
(1999) 276–285.
[34] Y. Gosiengﬁao, R. Horvat, A. Thompson, Transcription factors GATA-1 and Fli-1 reg-
ulate human HOXA10 expression in megakaryocytic cells, DNA Cell Biol. 26 (2007)
577–587.
[35] C. Buske, M. Feuring-Buske, J. Antonchuk, P. Rosten, D.E. Hogge, C.J. Eaves, R.K.
Humphries, Overexpression of HOXA10 perturbs human lymphomyelopoiesis
in vitro and in vivo, Blood 97 (2001) 2286–2292.
[36] M. Iwata, Retinoic acid production by intestinal dendritic cells and its role in T-cell
trafﬁcking, Semin. Immunol. 21 (2009) 8–13.
[37] Y.C. Lin, S. Jhunjhunwala, C. Benner, S. Heinz, E. Welinder, et al., A global network of
transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate,
Nat. Immunol. 11 (2010) 635–643.
[38] T. Kanaitsuka, Y. Namba, Y.L. Zu, K. Ishii, T. Ashihara, M. Hanaoka, T. Suchi, Detection
of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative
disorders, Leuk. Res. 13 (1989) 1025–1033.
[39] G. Troen, V. Nygaard, T.K. Jenssen, I.M. Ikonomou, A. Tierens, et al., Constitutive ex-
pression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the mar-
ginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma,
J. Mol. Diagn. 6 (2004) 297–307.
[40] C.M. Annunziata, L. Hernandez, R.E. Davis, A. Zingone, L. Lamy, L.T. Lam, E.M. Hurt,
A.L. Shaffer,W.M. Kuehl, L.M. Staudt, A mechanistic rationale for MEK inhibitor ther-
apy in myeloma based on blockade of MAF oncogene expression, Blood 117 (2011)
2396–2404.
[41] U. Thorsteinsdottir, G. Sauvageau, M.R. Hough, W. Dragowska, P.M. Lansdorp, H.J.
Lawrence, C. Largman, R.K. Humphries, Overexpression of HOXA10 inmurine hema-
topoietic cells perturbs both myeloid and lymphoid differentiation and leads to
acute myeloid leukemia, Mol. Cell. Biol. 17 (1997) 495–505.
[42] R.K. Gupta, Z. Arany, P. Seale, R.J. Mepani, L. Ye, H.M. Conroe, Y.A. Roby, H. Kulaga,
R.R. Reed, B.M. Spiegelman, Transcriptional control of preadipocyte determination
by Zfp423, Nature 464 (2010) 619–623.
[43] M. Francois, P. Richette, L. Tsagris, M. Raymondjean, M.C. Fulchignoni-Lataud, C.
Forest, J.F. Savouret, M.T. Corvol, Peroxisome proliferator-activated receptor-gamma
down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite ele-
ment, J. Biol. Chem. 279 (2004) 28411–28418.
[44] P. Delerive, F. Martin-Nizard, G. Chinetti, F. Trottein, J.C. Fruchart, J. Najib, P.
Duriez, B. Staels, Peroxisome proliferator-activated receptor activators inhibit
thrombin-induced endothelin-1 production in human vascular endothelial cells
by inhibiting the activator protein-1 signaling pathway, Circ. Res. 85 (1999)
394–402.
[45] M.E. Gershwin, D.R. Lentz, R.S. Beach, L.S. Hurley, Nutritional factors and autoimmu-
nity. IV. Dietary vitamin A deprivation induces a selective increase in IgM autoanti-
bodies and hypergammaglobulinemia in New Zealand Black mice, J. Immunol. 133
(1984) 222–226.
[46] S.M. Smith, C.E. Hayes, Contrasting impairments in IgM and IgG responses of vita-
min A-deﬁcient mice, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5878–5882.
[47] J.A. Carman, C.E. Hayes, Abnormal regulation of IFN-gamma secretion in vitamin A
deﬁciency, J. Immunol. 147 (1991) 1247–1252.
[48] J.H. Chang, H.R. Cha, S.Y. Chang, H.J. Ko, S.U. Seo, M.N. Kweon, IFN-gamma secreted
by CD103+ dendritic cells leads to IgG generation in the mesenteric lymph node in
the absence of vitamin A, J. Immunol. 186 (2011) 6999–7005.
